Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Coxeter
Oxford, Oxfordshire, United Kingdomblueearthdiagnostics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Coxeter is a biotechnology company specializing in the development of novel radiopharmaceuticals and radiochemistry technologies. Spun out from the University of Oxford, the company focuses on innovative methods for labeling molecules with fluorine-18 for use in Positron Emission Tomography (PET) imaging. Its proprietary technology aims to simplify and improve the production of PET tracers, particularly for oncology and neurology applications. Coxeter was acquired by Blue Earth Diagnostics in 2017 to bolster their molecular imaging pipeline and internal research capabilities. The company's work remains foundational to the development of next-generation PET imaging agents.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalSmall molecule
- Industry
- Biotech
02
Partnerships
University of Oxford
Beyond the preview
Go deeper on Coxeter.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coxeter.